Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 18, 2018--The “Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 22.214.171.124 or EC 126.96.36.199) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
According to the report; Macrophage Migration Inhibitory Factor pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.Report ScopeThe report provides a snapshot of the global therapeutic landscape for Macrophage Migration Inhibitory FactorThe report reviews Macrophage Migration Inhibitory Factor targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sourcesThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stagesThe report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activitiesThe report reviews key players involved in Macrophage Migration Inhibitory Factor targeted therapeutics and enlists all their major and minor projectsThe report assesses Macrophage Migration Inhibitory Factor targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule typeThe report summarizes all the dormant and discontinued pipeline projectsThe report reviews latest news and deals related to Macrophage Migration Inhibitory Factor targeted therapeuticsCompanies FeaturedGlaxoSmithKline plc Kyorin Pharmaceutical Co. Ltd.Shire plc
Featured News & Press ReleasesMediciNova reports positive results from SPRINT-MS trialMultiple sclerosis drug slows brain shrinkage in NIH-funded trialMediciNova to receive NIAAA funding for Phase llb trial of MNMediciNova to start Phase ll/lll trial of MN-166 for DCMMediciNova announces MN-166 (ibudilast) ALS abstract accepted for presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UKMediciNova Announces Full Enrollment in ALS Biomarker Clinical TrialYale researchers identify target for novel malaria vaccineMediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hjlht2/macrophage?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005540/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs ,Enzymes
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/18/2018 08:05 AM/DISC: 09/18/2018 08:05 AM